These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29966204)

  • 21. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
    Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
    Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
    Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
    J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.
    Koychev I; Gunn RN; Firouzian A; Lawson J; Zamboni G; Ridha B; Sahakian BJ; Rowe JB; Thomas A; Rochester L; Ffytche D; Howard R; Zetterberg H; MacKay C; Lovestone S;
    J Alzheimers Dis; 2017; 60(1):283-293. PubMed ID: 28800330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.
    Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD;
    JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.
    Yakushev I; Muller MJ; Buchholz HG; Lang U; Rossmann H; Hampel H; Schreckenberger M; Fellgiebel A
    Curr Alzheimer Res; 2012 Feb; 9(2):241-7. PubMed ID: 22044023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
    Hey JA; Abushakra S; Blennow K; Reiman EM; Hort J; Prins ND; Sheardova K; Kesslak P; Shen L; Zhu X; Albayrak A; Paul J; Schaefer JF; Power A; Tolar M
    Drugs; 2024 Jul; 84(7):811-823. PubMed ID: 38902571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms.
    Osorio RS; Pirraglia E; Gumb T; Mantua J; Ayappa I; Williams S; Mosconi L; Glodzik L; de Leon MJ
    Neurodegener Dis; 2014; 13(2-3):163-5. PubMed ID: 24107601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.
    Toledo JB; Weiner MW; Wolk DA; Da X; Chen K; Arnold SE; Jagust W; Jack C; Reiman EM; Davatzikos C; Shaw LM; Trojanowski JQ;
    Acta Neuropathol Commun; 2014 Mar; 2():26. PubMed ID: 24602322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.
    van Arendonk J; Neitzel J; Steketee RME; van Assema DME; Vrooman HA; Segbers M; Ikram MA; Vernooij MW
    Brain; 2023 Jan; 146(1):337-348. PubMed ID: 36374264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
    Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
    J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
    Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
    Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
    Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
    Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease.
    Senda M; Ishii K; Ito K; Ikeuchi T; Matsuda H; Iwatsubo T; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikari Y; Niimi Y; Arai H; Tamaoka A; Arahata Y; Itoh Y; Tachibana H; Ichimiya Y; Washizuka S; Odawara T; Ishii K; Ono K; Yokota T; Nakanishi A; Matsubara E; Mori H; Shimada H
    J Prev Alzheimers Dis; 2021; 8(4):495-502. PubMed ID: 34585225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.